Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
November 13, 2017 01:00 ET
|
NOVARTIS FINANCE S.A.
RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a...
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
November 12, 2017 21:50 ET
|
NOVARTIS FINANCE S.A.
Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of...
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
October 30, 2017 02:00 ET
|
NOVARTIS FINANCE S.A.
Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera®, a first-in-class RadioLigand Therapy (RLT)...
Novartis delivered growth on top and bottom line in all divisions in Q3
October 24, 2017 01:00 ET
|
NOVARTIS FINANCE S.A.
IFR (PDF)Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc)...
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
September 04, 2017 01:00 ET
|
NOVARTIS FINANCE S.A.
Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position....
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
August 30, 2017 11:04 ET
|
NOVARTIS FINANCE S.A.
First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes [1],[2]. Novel approach to cancer...
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
August 28, 2017 03:00 ET
|
NOVARTIS FINANCE S.A.
Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS...
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
August 28, 2017 03:00 ET
|
NOVARTIS FINANCE S.A.
Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885,...
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
July 18, 2017 01:00 ET
|
NOVARTIS FINANCE S.A.
Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications ...
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
July 12, 2017 17:24 ET
|
NOVARTIS FINANCE S.A.
Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is...